AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

Drugmaker AbbVie warned it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate, a ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses ...

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...